Boston-based Rhythm Pharmaceuticals has acquired worldwide rights from Ipsen to develop and commercialize drugs for diabetes, obesity and digestive diseases. The licensing deal calls for Rhythm to pay the French biotech firm as much as $80 million in milestone fees and royalties on future products.

Full Story:

Related Summaries